Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 28:14:1405778.
doi: 10.3389/fonc.2024.1405778. eCollection 2024.

Effect of different treatment modalities on the prognosis of patients with stage IIIC cervical cancer

Xiaoman Su  1 , Jiazhen Huang  1 , Ning Wang  1
Affiliations

Effect of different treatment modalities on the prognosis of patients with stage IIIC cervical cancer

Xiaoman Su et al. Front Oncol. .

Abstract

Objective: To compare the effects of different treatments on the prognosis of patients with stage IIIC cervical cancer and to identify the main influencing factors to predict the outcomes of patients.

Methods: In this study, a total of 1763 patients with stage IIIC cervical cancer from 2010-2015 were retrospectively analyzed, and these patients were divided into the radical radiotherapy ± chemotherapy group (877 patients) and the radical surgery + radiotherapy ± chemotherapy group (886 patients) according to the treatment methods. The survival differences between the two groups were compared using the Kaplan-Meier method. Unifactorial and multifactorial COX analyses screened the clinical factors affecting the prognosis. The nomogram was constructed, and the accuracy of the line graph was verified using the C-index, calibration, and ROC (receiver operator characteristic curve, ROC).

Results: Age, race, T-stage, pathologic type, mass size, whether or not they underwent surgery, and whether or not they received radiotherapy were independent factors affecting Overall Survival (OS). For all patients with TxN1M0 in cervical cancer stage IIIC, radical synchronized radiotherapy was better than the radical surgery group (p<0.0001). After comparing the tumor size breakdown, it could be found that in the T1N1M0, T2N1M0, and T3N1M0 groups, none of the OS in the surgical group achieved an improvement in OS compared with that in the non-surgical group (p>0.05).

Conclusion: In patients with stage IIIC cervical cancer, OS did not improve in the radical surgery group compared with the radical simultaneous radiotherapy group. And surgery did not benefit patients' survival regardless of tumor size.

Keywords: cervical cancer prognosis; lymph node metastasis; radiotherapy; stage IIIC cervical cancer; surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Materials and Methods. (B) The nomogram for OS in patients with stage IIIC cervical cancer.
Figure 2
Figure 2
(A) ROC curves of 1-year, 3-year, 5-year, and 8-year OS for training and validation sets. (B) Calibration curves for 1-year, 3-year, and 5-year OS of training and validation sets. (C) In patients with TxN1M0 ( Figure 2C ), radical synchronous radiotherapy was better than the radical surgery group.
Figure 3
Figure 3
(A–C) Whether in the patient with T1N1M0,T2N1M0 or T3N1M0,the OS of the radical synchronous radiotherapy group was higher than that of the radical surgery group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel Rl, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/Caac.21660 - DOI - PubMed
    1. Arbyn M, Weiderpass E, Bruni L, De Sanjosé S, Saraiya M, Ferlay J, et al. . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. (2020) 8:E191–191e203. doi: 10.1016/S2214-109x(19)30482-6 - DOI - PMC - PubMed
    1. Jinghui L, Jiao Y, Yanrong H. Research progress in early prevention and vaccine application of cervical cancer. J Chin Clin N Med. (2019) 12:377–80.
    1. Bhatla N, Aoki D, Sharma Dn, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. (2018) 143 Suppl 2:22–36. doi: 10.1002/Ijgo.12611 - DOI - PubMed
    1. Bhatla N, Js B, Cuello Fredes M, La D, Grenman S, Karunaratne K, et al. . Revised figo staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. (2019) 145:129–35. doi: 10.1002/Ijgo.12749 - DOI - PubMed

LinkOut - more resources